Organigram Global Inc. · TSX:OGI
Organigram Global — Q4 2023 Earnings Presentation
48 slides from Organigram Global's earnings presentation, Sep 30, 2023
Slide 1: Investor Presentation
INVESTOR PRESENTATION NASDAQ (OGI) TSX (OGI) Q4 Fiscal 2023 09 | 30 | 23 1
Slide 2: Cautionary Statement
CAUTIONARY STATEMENT This document is current as of September 30, 2023, except where otherwise management’s discussion and analysis and other Company documents filed from information under the heading "Cautionary Statement Regarding Certain Non- stated. The information contained in this presentation
Slide 3: Who We Are
WHO WE ARE 2022 Founded in 2013, we are an award-winning cannabis licensed producer with operations spread across Canada Our Vision: To be a respected global leader in the emerging cannabis movement 2023 Our Mission: To delight consumers with trusted brands that deliver innovative cannabis products
Slide 4: Our Strategy
OUR STRATEGY INNOVATION CONSUMER FOCUS EFFICIENCY EXPANSION Leverage our brands, product portfolio and culture of innovation to: Increase Drive Deliver long-term Reach market share profitability shareholder value new markets 4
Slide 5: Near-Term Strategy
NEAR-TERM STRATEGY • Organigram continues to demonstrate a track record of innovation informed by consumer research, resulting in market share increases in several categories: • Revolutionized hash with SHRED X Rip-Strips • First to market with ingestible extracts and milled flower • Introducing who
Slide 6: Long-Term Strategy
LONG-TERM STRATEGY • Organigram has strategically deployed capital to fuel automation, production efficiency, and product consistency needed to attract and retain international distribution partners: • Production and packaging lines for gummies, milled flower, and pre-rolls are now highly automated
Slide 7: Organigram Key Strengths
ORGANIGRAM KEY STRENGTHS STRONG STATE-OF-THE- HIGH NATIONAL & INNOVATION EXCELLENCE IN BALANCE SHEET ART FACILITIES PERFORMING INTERNATIONAL FOCUS EXECUTION REACH • Negligible debt (less • Moncton facility is one • $233.6M gross • National sales and • First to market with • Consumer insights- than $
Slide 8: BAT Strategic Investments in Organigram
BAT STRATEGIC INVESTMENTS IN ORGANIGRAM March 2021 - $221M strategic investment from subsidiary of BAT for 19.9% equity interest1 in Organigram • Product Development Collaboration (PDC) with formation of a Center of Excellence (CoE) at our Moncton campus • Focused on developing the next generation o
Slide 9: Established Trend of Revenue Growth
ESTABLISHED TREND OF REVENUE GROWTH $233.6 Annual Revenue $ millions $209.1 $161.6 $145.8 $109.8 $103.3 $97.5 $86.7 $80.4 $79.1 1 F2019 F2020 F2021 F2022 F2023 Net Revenue Gross Revenue 1. Fiscal 2023 represents 13 months due to a change in 9 Organigram's year end.
Slide 10: Significant International Sales Growth
SIGNIFICANT INTERNATIONAL SALES GROWTH $18.9 $15.1 INTERNATIONAL NET REVENUE1 $ millions High margin international sales expected to increase further in F2024 $3.8 1. International shipments do not attract Canadian Federal excise taxes and therefore gross, and net revenues are equal. 2. Fiscal 2023
Slide 11: Quarterly Updates & Highlights
QUARTERLY UPDATES & HIGHLIGHTS Q4 F2023 11
Slide 12: A Leading Canadian LP
A LEADING CANADIAN LP #2 market share among Canadian LPs1 #1 share for milled flower, #1 in hash, #1 in gummies, #2 in edibles, #3 in pre-rolls, #3 in flower1 #1 LP in Atlantic Canada, #3 in Ontario, #3 in Quebec1 1. As of September 30, 2023 – Multiple Sources (Hifyre, Weedcrawler, provincial boards
Slide 13: Adjusted Gross Margin
ADJUSTED GROSS MARGIN $40.2 $33.4 ADJUSTED GROSS MARGIN1 $ millions and % of Net Revenue 1. Adjusted gross margin is a non-IFRS financial measure 26% 24% 23% not defined under IFRS and which does not have any $3.6 standardized meaning under IFRS; please refer to the cautionary statement at the begin
Slide 14: Adjusted EBITDA
ADJUSTED EBITDA $6.0 $3.5 ADJUSTED EBITDA1 $ millions 1. Adjusted EBITDA is a non-IFRS Financial Measure not defined by and does not have any standardized meaning under IFRS; please refer to the cautionary statement at the beginning of this document and the Company’s 2023 MD&A for definitions and a
Slide 15: F2023 Market Successes
F2023 MARKET SUCCESSES • Organigram achieved the #2 national market share position1 • Held the #1 position in milled flower, the #1 position in concentrates, and moved into the #1 position in gummies nationally1 • Introduced Tube-Style Pre-Rolls and went from #10 to #3 market share in overall Pre-Ro
Slide 16: F2023 Strategic Highlights
F2023 STRATEGIC HIGHLIGHTS • First U.S. strategic investment and technical arrangement with Phylos to commercialize THCV and convert a portion of garden to cost effective seed-based production • Accelerated focus on vapes with a strategic investment in Greentank, a leading vaporization technology co
Slide 17: Strong Balance Sheet and Liquidity
STRONG BALANCE SHEET AND LIQUIDITY • On September 30, 2023, the Company had cash of $51.8 million (including restricted cash) • $124.6 million follow-on investment from BAT announced November 6, 2023, expected to enhance capital position and fuel international growth • Negligible debt (less than $0.
Slide 18: Q4 Fiscal 2023 Key Financial Metrics
Q4 FISCAL 13- 12- months en months end Q4‘23 Q4‘22 % Change ded Sep‘23 ed Aug‘22 % Change 2023 KEY Gross revenue 71.5 65.7 9% 233.6 209.1 12% Excise taxes (25.4) (20.2) 26% (72.0) (63.3) 14% FINANCIAL Net revenue1 46.0 45.5 1% 161.6 145.8 11% Cost of sales 42.9 36.7 17% 136.4 119.0 15% METRICS Gross
Slide 19: Fiscal 2024 Outlook
FISCAL 2024 OUTLOOK • Expecting solid Fiscal ‘24 net revenue – anticipated to be higher than Fiscal ‘23 due to: • Strong market share – positioned as the #2 LP1 • Continued expansion of product portfolio in multiple segments • Focus on expansion in key growth categories of vapes and pre-rolls • Grea
Slide 20: Potential Upside for Gross Margins
POTENTIAL UPSIDE FOR GROSS MARGINS • Improved economies of scale and efficiencies as cultivation and production volumes continue to increase • Leverage the increased annual capacity at Moncton facility and dialing in 2023 capex investments – targeting ~$10 million in savings in F2024 • Conversion of
Slide 21: Brand Portfolio
BRAND PORTFOLIO 21
Slide 22: Well-Rounded Brand Portfolio
WELL-ROUNDED BRAND PORTFOLIO NEW Pricing Segment Value Value Value Mainstream Mainstream Mainstream Premium Craft Pre-Milled Flower, Pre-Roll Joints, Pre-Rolls, Available / Whole Flower, Hashish, Infused Gummies, Whole Flower CBD & Minor Infused Pre-Rolls, Whole Flower Planned Whole Flower Pre-Roll
Slide 23: Consumer Segmentation
CONSUMER SEGMENTATION Cheap High Male Lifestyle Passionate Female Therapeutic Problem SEGMENT Premium Craft Seeker Social Dabbler Urban Trend Follower Chaser Enthusiast Believer Solver % CONSUMERS 15% 13% 6% 12% 20% 25% 10% Canada vs ATL % VOLUME Canada vs ATL 23% 12% 11% 27% 13% 3% 11% • Seeking th
Slide 24: Dynamic Brand Performance
DYNAMIC BRAND PERFORMANCE Rip-Strip Sales Have Exploded Monjour Market Share has Doubled Organigram is the #1 LP in vs. Prior Year Concentrates • Launched in March 2023 • Monjour holds over half of the pure- • Organigram holds >23% of national • Over 260K units sold approaching CBD national market s
Slide 25: Dynamic Brand Performance
DYNAMIC BRAND PERFORMANCE SHRED X Heavies – 40%+ THC Infused Pre-Rolls (IPRs) Tube Style Pre-Rolls • IPR's are fastest growing category in Canada (125% • Tube style pre roll segment growing at 30% year- YOY growth) over-year • Launched end of May 2023 • Organigram market share in tube-style pre-roll
Slide 26: Operations
OPERATIONS 26
Slide 27: Moncton: State-of-Art Cultivation Centre
MONCTON: STATE-OF- ART CULTIVATION CENTRE ~85,000 kg/year of low-cost high-quality indoor flower • 500,000 sq. Ft. campus located in Moncton, NB – One of the largest indoor cannabis facilities in the world • Unique, modular, three-tier, strain-specific grow rooms with 245,000 sq. Ft. of growing spac
Slide 28: Lac Supérieur: Premium Quality Cannabis and Hash Production
LAC SUPÉRIEUR: PREMIUM QUALITY CANNABIS AND HASH PRODUCTION Acquired in Q2 F2021 - drove #1 market share of hash by Q1 F20231 • Located in Lac-Supérieur, Québec (near Mont-Tremblant) • Producer of hang dried, trimmed by hand, artisanal craft cannabis, and premium Afghan-style hash • 30,000 sq. ft. e
Slide 29: Winnipeg: Edibles and Derivatives Facility
WINNIPEG: Large scale automation and innovative products EDIBLES AND • Purpose-built, highly automated, 51,000 sq. ft. facility with state-of-the-art equipment • Designed to produce nutraceutical-grade cannabis edibles, including pectin, gelatin, DERIVATIVES and sugar-free soft chews (gummies), toff
Slide 30: Strategic Investments
STRATEGIC INVESTMENTS 30
Slide 31: Investment in Disruptive Vaping Technology
INVESTMENT IN DISRUPTIVE VAPING TECHNOLOGY • In March of 2023, Organigram invested C$5.5M into Greentank, a vape R&D firm and hardware manufacturer • Greentank's heating technology is the first meaningful innovation in the vape space in almost a decade • Invented a novel heating element which replac
Slide 32: Investment in Seed Genetics & THCV
INVESTMENT IN SEED GENETICS & THCV • In May of 2023, Organigram made its first investment into the U.S cannabis market by issuing a strategic convertible loan to Phylos • Phylos will enable Organigram to accelerate the launch of products containing THCV in the Canadian market – THCV provides consume
Slide 33: Investment in Disruptive Technology-Biosynthesis
INVESTMENT IN DISRUPTIVE TECHNOLOGY-BIOSYNTHESIS BIOSYNTHESIS How it works? A proprietary Biosynthesis can be used to produce cannabinoids that are identical to those • 49% ownership (if convertible debt converted) of Hyasynth cannabinoid manufacturing produced by the plant itself. Biologicals Inc.,
Slide 34: International
INTERNATIONAL 34
Slide 35: Key International Supply Arrangements
KEY INTERNATIONAL SUPPLY ARRANGEMENTS • Currently shipping to medical markets in Australia and Israel • In F2023 shipped $18.9 million in flower vs. $15.1 million in full year F2022 • November 17, 2022: entered into a new multi-year Strategic Agreement with Canndoc to supply up to 20,000kg of dry fl
Slide 36: Appendix
APPENDIX 36
Slide 37: March 2021 BAT Transaction Summary
MARCH 2021 BAT TRANSACTION SUMMARY • Subsidiary of BAT subscribed for 58.3M common shares of Organigram, which represented a 19.9% equity interest in March 20211 on a post-transaction basis • Total proceeds to Organigram in March 2021 of ~C$221 million (the “Investment Proceeds”) Investment • The pr
Slide 38: November 2023 BAT Transaction Summary
NOVEMBER 2023 BAT TRANSACTION SUMMARY • Subject to requisite Organigram shareholder approval, regulatory approvals and other conditions, subsidiary of BAT to subscribe for, in aggregate, ~38.7 million shares of Organigram, over three tranches, at C$3.2203/share. • Total gross proceeds to Organigram
Slide 39: An uplifting & vibrant value brand focused on convenience
An uplifting & vibrant value brand focused on convenience. Tropic Thunder 7g pre-milled Wild Berry Blaze SHRED’ems Gnarberry 1g 510 vape SHRED X Rip Strips 39
Slide 40: An imaginative brand with iconic strains and stellar extracts
An imaginative brand with iconic strains and stellar extracts. Holy Mountain Mac-1 3.5 g, R*ntz 3.5g, Pressed Hash 40
Slide 41: Delivering high-quality ounces in a variety of strains
Delivering high-quality ounces in a variety of strains. Pink Cookies I.C.C. Ultra Sour 41
Slide 42: CBD and minor cannabinoid gummies
CBD and minor cannabinoid gummies, designed for a personal wellness ritual. Monjour Berry Good Day Monjour Orchard Medley 42
Slide 43: A premium brand focused on flower & innovation
A premium brand focused on flower & innovation. Limelight 3.5g dried flower Edison JOLTS – Electric Lemon Cherry Limelight Bubble Hash Joints 43
Slide 44: Premium hash, inspired by the timeless tradition of hashish
Premium hash, inspired by the timeless tradition of hashish. Tremblant 2g Hash 44
Slide 45: Craft cannabis featuring rare cultivars
Craft cannabis featuring rare cultivars grown with utmost attention and care. Laurentian Saisons 3.5 g 45
Slide 46: Q4 Fiscal 2023 Select Balance Sheet Metrics
Q4 FISCAL 2023 SELECT BALANCE SHEET METRICS SELECT BALANCE SHEET METRICS September 30, 2023 Aug 31, 2022 % Change Cash & short-term investments (excluding restricted cash) 33,864 98,607 (66)% Biological assets & inventories 80,953 68,282 19% Other current assets 50,066 54,734 (9)% In $000s unless Ac
Slide 47: Q4 Fiscal 2023 Capital Structure
Q4 FISCAL 2023 CAPITAL STRUCTURE Sept 30, AUGUST 31, in $000s 2023 2022 Current and long-term debt 155 235 Shareholders’ equity 272,093 508,058 Total debt and shareholders’ equity 272,048 508,293 in 000s Outstanding common shares 81,162 313,816 Options 2,830 11,051 Warrants 4,236 16,944 Top-up right
Slide 48: A Canadian Cannabis Leader
A CANADIAN CANNABIS LEADER NASDAQ (OGI) TSX (OGI) 48